Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 4

1.

Clinical, quality of life, and economic value of acromegaly disease control.

Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S.

Pituitary. 2011 Sep;14(3):284-94. doi: 10.1007/s11102-011-0310-7. Review.

2.

Growth hormone status predicts left ventricular mass in patients after cure of acromegaly.

Wexler TL, Durst R, McCarty D, Picard MH, Gunnell L, Omer Z, Fazeli P, Miller KK, Klibanski A.

Growth Horm IGF Res. 2010 Oct;20(5):333-7. doi: 10.1016/j.ghir.2010.05.003. Epub 2010 Jul 3.

3.

The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome.

Klibanski A, Melmed S, Clemmons DR, Colao A, Cunningham RS, Molitch ME, Vinik AI, Adelman DT, Liebert KJ.

Pituitary. 2010 Sep;13(3):266-86. doi: 10.1007/s11102-009-0210-2. Review.

4.

Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

Roelfsema F, Biermasz NR, Pereira AM, Romijn JA.

Biologics. 2008 Sep;2(3):463-79.

Supplemental Content

Support Center